Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunic gets a "positive surprise" from lead asset trial

By: News Direct

--News Direct--

Immunic Inc (NASDAQ: IMUX) CEO Dr. Daniel Vitt speaks to Proactive following the release of data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset vidofludimus calcium (IMU-838) in patients with moderate-to-severe ulcerative colitis (UC).

Vitt describes it as "wonderful data" that came as a "positive surprise."

Contact Details

Proactive United States

Proactive United States

+1 347-449-0879

action@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/immunic-gets-a-positive-surprise-from-lead-asset-trial-619463718

Recent Quotes

View More
Symbol Price Change (%)
AMZN  206.31
+1.04 (0.51%)
AAPL  273.53
+7.35 (2.76%)
AMD  209.30
+12.70 (6.46%)
BAC  49.52
-1.55 (-3.03%)
GOOG  306.74
-4.95 (-1.59%)
META  632.70
-4.55 (-0.71%)
MSFT  386.40
+1.93 (0.50%)
NVDA  190.95
-0.60 (-0.31%)
ORCL  144.61
+3.30 (2.34%)
TSLA  402.36
+2.53 (0.63%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.